VIRI Dogwood Therapeutics Inc.


$ 5.65 $ -0.56 (-9.05 %)    

Tuesday, 21-Oct-2025 16:59:09 EDT
QQQ $ 610.29 $ -0.16 (-0.03 %)
DIA $ 469.10 $ 2.20 (0.47 %)
SPY $ 670.98 $ -0.01 (0 %)
TLT $ 91.99 $ 0.45 (0.49 %)
GLD $ 376.61 $ -25.91 (-6.43 %)
$ 5.63
$ 6.13
$ 5.14 x 3
$ 6.20 x 100
$ 5.63 - $ 6.13
$ 1.62 - $ 29.28
40,961
na
na
$ 2.26
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-neutral-on-virios-therapeutics-adjusts-price-target-to-5-25-1-reverse-stock-split

HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral, adjusts target to $5 from ...

Core News & Articles

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), and Wex Pharmaceuticals, Inc. ("WEX"), a wholly owned ...

 hc-wainwright--co-maintains-neutral-on-virios-therapeutics-lowers-price-target-to-02

HC Wainwright & Co. analyst Sean Lee maintains Virios Therapeutics (NASDAQ:VIRI) with a Neutral and lowers the price tar...

 virios-therapeutics-q2-2024-gaap-eps-005-inline

Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This...

 maxim-group-initiates-coverage-on-virios-therapeutics-with-buy-rating-announces-price-target-of-1

Maxim Group analyst Jason McCarthy initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces P...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION